Dr. Desai describes the findings of over 1800 patients obstructive HCM in which they reviewed the 5-year primary event rate across the 3 ESC SCD risk categories. The results of this paper shows that…
Dr. Steve Nissen discusses the results of three important late breaking trials looking at the impact of three drugs on cardiovascular endpoints: the CANTOS trial (Canakinumab); the REVEAL study…